Literature DB >> 15867479

VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma.

Anne Talvensaari-Mattila1, Ylermi Soini, Markku Santala.   

Abstract

Vascular endothelial growth factor (VEGF) is associated with increased angiogenesis and aggressive tumour growth. We investigated the expression and clinical significance of VEGF and its receptors, flt-1 and KDR/flk-1, in patients with uterine endometrial carcinoma. The series consisted of 115 endometrioid endometrial adenocarcinoma patients with FIGO stage I-IV. Additionally, samples from 3 patients with adenoacanthoma and 12 patients with poor prognostic variants of endometrial carcinoma were examined. Immunohistochemical assessment was classified as negative or positive based on staining intensity. The median follow-up time of patients with endometrioid endometrial adenocarcinoma was 87 months. In endometrioid endometrial carcinomas, the positive immunostaining rate was 39% for VEGF, 65% for flt-1 and 68% for KDR/flk-1. There was a significant correlation between VEGF and both its receptors. Furthermore, this receptor expression was correlated between the two types of receptors. VEGF-, flt-1- and KDR/flk-1-positive immunostainings were not related to poor prognosis. We conclude that VEGF, flt-1 and KDR/flk-1 expressions are not useful prognostic markers for overall survival in patients with endometrioid endometrial carcinoma. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15867479     DOI: 10.1159/000085589

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

1.  A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

Authors:  Kathleen N Moore; Michael W Sill; Meaghan E Tenney; Christopher J Darus; David Griffin; Theresa L Werner; Peter G Rose; Robert Behrens
Journal:  Gynecol Oncol       Date:  2015-07-11       Impact factor: 5.482

2.  A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Michael W Sill; Doris Benbrook; Kathleen M Darcy; Deborah J Stearns-Kurosawa; Lynne Eaton; S Diane Yamada
Journal:  Gynecol Oncol       Date:  2007-02-15       Impact factor: 5.482

Review 3.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

4.  Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.

Authors:  Sami K Saarelainen; Synnöve Staff; Nina Peltonen; Terho Lehtimäki; Jorma Isola; Paula M Kujala; Maarit H Vuento; Johanna U Mäenpää
Journal:  Tumour Biol       Date:  2014-01-14

5.  A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Heather A Lankes; Amanda Nickles Fader; Neil J Finkler; James S Hoffman; Peter G Rose; Gregory P Sutton; Charles W Drescher; D Scott McMeekin; Wei Hu; Michael Deavers; Andrew K Godwin; R Katherine Alpaugh; Anil K Sood
Journal:  Gynecol Oncol       Date:  2012-08-23       Impact factor: 5.482

6.  Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.

Authors:  Vicky Makker; Virginia L Filiaci; Lee-May Chen; Christopher J Darus; James E Kendrick; Gregory Sutton; Katherine Moxley; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2015-04-16       Impact factor: 5.482

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.